Key Drivers
- Improved margins
- Heavy leverage
- Weak cash flow
AIAI Summary
AMRX is shifting from a “cheap pharma” value play to an execution-driven transition story: margins and liquidity are improving, but the stock will likely stay capped unless management can replace Rytary-driven Specialty erosion with launches/Kashiv growth and turn earnings into consistent free cash flow.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Improved margins
- •Heavy leverage
- •Weak cash flow
AMRX posted a strong quarter with better margins, improved interest coverage, and solid liquidity, but negative equity, high debt, and weak cash conversion still make the story risky.
Price Behavior
Key Price Behavior Insights:
- •Broken support
- •Failed breakout
- •Lower highs
AMRX remains in a clear downtrend over the last month, with the failed rally into May quickly reversing, support at $12.50 to $12.80 broken, and resistance holding near $13.40 to $13.90, so caution is warranted.
Rally to $13.72 on 2026-05-07 quickly reversed into new lows
Sentiment & News
Key News Insights:
- •Earnings Beat
- •Biosimilar Expansion
- •Specialty Pressure
Amneal is gaining momentum with better-than-expected Q1 results, raised guidance, and a strategic Kashiv BioSciences acquisition, though Specialty weakness and Rytary erosion still temper the outlook.
The news flow is bullish for AMRX overall, as improving fundamentals and strategic diversification appear to outweigh segment-level headwinds
Similar Companies in Healthcare
Other companies in the same sector with AI ratings